• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The renal elimination of procainamide.

作者信息

Galeazzi R L, Sheiner L B, Lockwood T, Benet L Z

出版信息

Clin Pharmacol Ther. 1976 Jan;19(1):55-62. doi: 10.1002/cpt197619155.

DOI:10.1002/cpt197619155
PMID:1171
Abstract

The question of pH or flow dependence for the renal elimination of procainamide (PCA) was studied under 4 conditions in each of 4 subjects. Each subject received 500 mg of PCA intravenously at weekly intervals while in a state of (1) acid load (NH4Cl) and water deprivation, (2) acid load and water excess, (3) alkali load (NaHCO3) and water deprivation, and (4) alkali load and water excess. Plasma and urine were collected at frequent intervals for PCA and N-acetyl PCA (NAPA) analysis. Urine flow rates varied markedly between the water deprivation and water excess states (approximately 1.2 vs 5 ml/min, respectively), and urine pH varied markedly between the acid and alkali load states (pH = ca 5 vs 8, respectively). Despite this marked variation, there were no significant changes in PCA renal clearance or 24-hr PCA or NAPA excretion. If passive diffusion of PCA were taking place, such flow and pH changes would have caused marked changes in PCA clearance were the pH partition hypothesis true. We therefore conclude that passive diffusion is not an important mechanism in the renal elimination of PCA in man and that there must be tubular secretion. The implication for the clinical use of the drug is that dose adjustments need not be made in response to variations in urine flow and pH.

摘要

相似文献

1
The renal elimination of procainamide.
Clin Pharmacol Ther. 1976 Jan;19(1):55-62. doi: 10.1002/cpt197619155.
2
Polymorphic acetylation procainamide in man.人体内普鲁卡因酰胺的多态性乙酰化
Clin Pharmacol Ther. 1975 Jun;17(6):722-30. doi: 10.1002/cpt1975176722.
3
Kinetics of procainamide and N-acetylprocainamide in renal failure.肾衰竭患者中普鲁卡因胺和N - 乙酰普鲁卡因胺的动力学
Kidney Int. 1977 Dec;12(6):422-9. doi: 10.1038/ki.1977.133.
4
Procainamide pharmacokinetics in beagles: urinary pH dependency and comparison with n-acetylprocainamide.
Res Commun Chem Pathol Pharmacol. 1977 Jun;17(2):333-6.
5
Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.采用稳定同位素方法同时研究普鲁卡因胺和N-乙酰普鲁卡因胺的动力学。
Clin Pharmacol Ther. 1977 Oct;22(4):447-57. doi: 10.1002/cpt1977224447.
6
Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype.普鲁卡因胺在人体内的乙酰化及其与异烟肼乙酰化表型的关系。
Clin Pharmacol Ther. 1975 Apr;17(4):395-9. doi: 10.1002/cpt1975174395.
7
Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man.雷尼替丁对人体内普鲁卡因胺处置和肾清除率的剂量及浓度依赖性效应。
Br J Clin Pharmacol. 1984 Aug;18(2):175-81. doi: 10.1111/j.1365-2125.1984.tb02450.x.
8
Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition.蛋白质 - 热量营养不良时普鲁卡因胺和N - 乙酰普鲁卡因胺的处置
Drug Metab Dispos. 1985 May-Jun;13(3):359-63.
9
Renal excretion of pseudoephedrine.伪麻黄碱的肾脏排泄。
Clin Pharmacol Ther. 1980 Nov;28(5):690-4. doi: 10.1038/clpt.1980.222.
10
Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.健康受试者中普鲁卡因胺(PA)和N-乙酰普鲁卡因胺(NAPA)的药代动力学研究。
Int J Clin Pharmacol Ther Toxicol. 1980 Jun;18(6):272-6.

引用本文的文献

1
Physiologically-Based Pharmacokinetic Modeling for Drug-Drug Interactions of Procainamide and -Acetylprocainamide with Cimetidine, an Inhibitor of rOCT2 and rMATE1, in Rats.基于生理学的普鲁卡因胺和N - 乙酰普鲁卡因胺与西咪替丁(一种rOCT2和rMATE1抑制剂)在大鼠体内药物相互作用的药代动力学模型。
Pharmaceutics. 2019 Mar 6;11(3):108. doi: 10.3390/pharmaceutics11030108.
2
Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.人体中某些磺胺类药物乙酰化表型及药代动力学的测定
Clin Pharmacokinet. 1980 May-Jun;5(3):274-94. doi: 10.2165/00003088-198005030-00006.
3
The pharmacological role of the kidney.
肾脏的药理学作用。
Drugs. 1980 Jan;19(1):31-48. doi: 10.2165/00003495-198019010-00003.
4
Population pharmacokinetics of procainamide from routine clinical data.基于常规临床数据的普鲁卡因胺群体药代动力学
Clin Pharmacokinet. 1984 Nov-Dec;9(6):545-54. doi: 10.2165/00003088-198409060-00004.
5
Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs.西咪替丁与普鲁卡因胺在人体中的药代动力学相互作用:碱性药物肾小管分泌竞争的证据。
Eur J Clin Pharmacol. 1983;25(3):339-45. doi: 10.1007/BF01037945.
6
Clinical pharmacokinetics of N-acetylprocainamide.N-乙酰普鲁卡因胺的临床药代动力学
Clin Pharmacokinet. 1982 May-Jun;7(3):206-20. doi: 10.2165/00003088-198207030-00002.
7
Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man.雷尼替丁对人体内普鲁卡因胺处置和肾清除率的剂量及浓度依赖性效应。
Br J Clin Pharmacol. 1984 Aug;18(2):175-81. doi: 10.1111/j.1365-2125.1984.tb02450.x.
8
Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.IA类抗心律失常药物中毒。奎尼丁、普鲁卡因胺和丙吡胺。
Drug Saf. 1990 Nov-Dec;5(6):393-420. doi: 10.2165/00002018-199005060-00002.
9
Pharmacokinetics in patients with cardiac failure.心力衰竭患者的药代动力学。
Clin Pharmacokinet. 1976 Nov-Dec;1(6):389-405. doi: 10.2165/00003088-197601060-00001.
10
Serum procainamide levels as therapeutic guides.作为治疗指导的血清普鲁卡因胺水平。
Clin Pharmacokinet. 1977 Nov-Dec;2(6):389-402. doi: 10.2165/00003088-197702060-00001.